Effect of high-dose intravenous steroid pulse therapy followed by 3-month oral steroid therapy for Graves' ophthalmopathy

被引:16
作者
Ohtsuka, K [1 ]
Sato, A [1 ]
Kawaguchi, S [1 ]
Hashimoto, M [1 ]
Suzuki, Y [1 ]
机构
[1] Sapporo Med Coll, Dept Ophthalmol, Chuo Ku, Sch Med, Sapporo, Hokkaido 060, Japan
关键词
extraocular muscle hypertrophy; Graves' disease; Graves' ophthalmopathy; proptosis; steroid pulse therapy;
D O I
10.1016/S0021-5155(02)00544-0
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To evaluate the effect of high-dose intravenous steroid pulse therapy followed by 3-month oral steroid therapy for Graves' ophthalmopathy. Methods: We selected 41 Japanese patients (age range, 21-76 years; mean = 49 years) who had active Graves' ophthalmopathy among 205 consecutive patients examined at Sapporo Medical University Hospital between 1997 and 1999. In a prospective study, we investigated the effect on the 41 patients of high-dose intravenous methylprednisolone pulse therapy (1 g/day X 3 days X 3 times) followed by 3-month oral prednisone therapy. Coronal computed tomography (CT) of the orbit, exophthalmometry and monocular fixation field measured by Goldmann perimetry were carried out before the steroid pulse therapy, and 1 and 6 months after the steroid pulse therapy. The maximum coronal section area of the rectus muscle in each eye was measured using an orbital CT image. Results: Extraocular muscle hypertrophy was significantly reduced I and 6 months after the pulse therapy (paired t-test, P < .01), and was not significantly different between I and 6 months after the pulse therapy. Proptosis was not significantly reduced by the pulse therapy. Monocular fixation fields were measured in 34 patients with diplopia, and limitation of eye movements was improved in 15 patients (44%) by the pulse therapy. In the other patients, improvement of the limitation was not detectable by the test of the monocular fixation field. Conclusions: The treatment in this study is effective for extraocular muscle hypertrophy, and relapse was minimum within 6 months. However, this treatment has limited effect on limitation of eye movements and less effect on proptosis. (C) 2002 Japanese Ophthamological Society.
引用
收藏
页码:563 / 567
页数:5
相关论文
共 14 条
[1]   RETROOCULAR FIBROBLASTS - IMPORTANT EFFECTOR-CELLS IN GRAVES OPHTHALMOPATHY [J].
BAHN, RS ;
HEUFELDER, AE .
THYROID, 1992, 2 (01) :89-94
[2]  
CAMPBELL RJ, 1989, ACTA ENDOCRINOL-COP, V121, P9
[3]   CORTICOSTEROIDS IN TREATMENT OF OPTIC NERVE INVOLVEMENT - ASSOCIATED WITH THYROID DYSFUNCTION [J].
DAY, RM ;
CARROLL, FD .
ARCHIVES OF OPHTHALMOLOGY, 1968, 79 (03) :279-&
[4]  
GUY JR, 1989, OPHTHALMOLOGY, V96, P1048
[5]   INTRAVENOUS METHYLPREDNISOLONE PULSE THERAPY FOR GRAVES OPHTHALMOPATHY [J].
HIROMATSU, Y ;
TANAKA, K ;
SATO, M ;
KUROKI, T ;
NONAKA, K ;
KOJIMA, K ;
NISHIMURA, H ;
NISHIDA, H ;
KAISE, N .
ENDOCRINE JOURNAL, 1993, 40 (01) :63-72
[6]   EFFECT OF GROWTH-FACTORS ON HYALURONAN AND PROTEOGLYCAN SYNTHESIS BY RETROOCULAR TISSUE FIBROBLASTS OF GRAVES OPHTHALMOPATHY IN CULTURE [J].
IMAI, Y ;
ODAJIMA, R ;
INOUE, Y ;
SHISHIBA, Y .
ACTA ENDOCRINOLOGICA, 1992, 126 (06) :541-552
[7]   ENDOCRINE OPHTHALMOPATHY - CURRENT IDEAS CONCERNING ETIOLOGY, PATHOGENESIS, AND TREATMENT [J].
JACOBSON, DH ;
GORMAN, CA .
ENDOCRINE REVIEWS, 1984, 5 (02) :200-220
[8]   Intravenous methylprednisolone pulse therapy in the treatment of Graves' ophthalmopathy [J].
Matejka, G ;
Vergès, B ;
Vaillant, G ;
Petit, JM ;
Brun-Pacaud, A ;
Rudoni, S ;
Brun, JM .
HORMONE AND METABOLIC RESEARCH, 1998, 30 (02) :93-98
[9]   CLINICAL-CRITERIA FOR THE ASSESSMENT OF DISEASE-ACTIVITY IN GRAVES OPHTHALMOPATHY - A NOVEL-APPROACH [J].
MOURITS, MP ;
KOORNNEEF, L ;
WIERSINGA, WM ;
PRUMMEL, MF ;
BERGHOUT, A ;
VANDERGAAG, R .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1989, 73 (08) :639-644
[10]   TREATMENT OF GRAVES OPHTHALMOPATHY WITH HIGH-DOSE INTRAVENOUS METHYLPREDNISOLONE PULSE THERAPY [J].
NAGAYAMA, Y ;
IZUMI, M ;
KIRIYAMA, T ;
YOKOYAMA, N ;
MORITA, S ;
KAKEZONO, F ;
OHTAKARA, S ;
MORIMOTO, I ;
OKAMOTO, S ;
NAGATAKI, S .
ACTA ENDOCRINOLOGICA, 1987, 116 (04) :513-518